{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:10:23Z","timestamp":1785852623879,"version":"3.56.0"},"reference-count":68,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AO Start-Up","award":["S-16-138W"],"award-info":[{"award-number":["S-16-138W"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Zoledronate (Zol) is an anti-resorptive\/tumoral agent used for the treatment of many cancers including spinal bone metastasis. High systemic administration of a single dose is now the standard clinical care, yet it has been associated with several side effects. Here, we aimed to evaluate the effects of lower doses Zol on lung cancer and lung cancer-induced bone metastasis cells over a longer time period. Human lung cancer (HCC827) and three bone metastases secondary to lung cancer (BML1, BML3 and BML4) cells were treated with Zol at 1, 3 and 10 \u00b5M for 7 days and then assessed for cell proliferation, migration, invasion and apoptosis. Low Zol treatment significantly decreased cell proliferation (1, 3 and 10 \u00b5M), migration (3 and 10 \u00b5M) and invasion (10 \u00b5M) while increasing apoptosis (10 \u00b5M) in lung cancer and metastatic cells. Our data exploits the potential of using low doses Zol for longer treatment periods and reinforces this approach as a new therapeutic regimen to impede the development of metastatic bone cancer while limiting severe side effects following high doses of systemic drug treatment.<\/jats:p>","DOI":"10.3390\/jcm8081212","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T04:22:54Z","timestamp":1565842974000},"page":"1212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis"],"prefix":"10.3390","volume":"8","author":[{"given":"Elie","family":"Akoury","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair &amp; Recovery program, Montreal, QC H3G 1A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-4052","authenticated-orcid":false,"given":"Ana Sofia","family":"Ramirez Garcia Luna","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair &amp; Recovery program, Montreal, QC H3G 1A4, Canada"},{"name":"Medical Faculty Mannheim, Heidelberg University, D-68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouyan","family":"Ahangar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair &amp; Recovery program, Montreal, QC H3G 1A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair &amp; Recovery program, Montreal, QC H3G 1A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pylyp","family":"Zolotarov","sequence":"additional","affiliation":[{"name":"Department of Pathology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair &amp; Recovery program, Montreal, QC H3G 1A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-8177","authenticated-orcid":false,"given":"Derek H.","family":"Rosenzweig","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair &amp; Recovery program, Montreal, QC H3G 1A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_3","unstructured":"PDQ\u00ae Adult Treatment Editorial Board (2019). Non-Small Cell Lung Cancer Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries, Bethesda."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1378\/chest.07-1347","article-title":"Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Alberg","year":"2007","journal-title":"Chest"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1158\/1055-9965.EPI-04-0570","article-title":"Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers","volume":"14","author":"Tulunay","year":"2005","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1258\/jms.2008.008052","article-title":"Low-dose lung computed tomography screening before age 55: Estimates of the mortality reduction required to outweigh the radiation-induced cancer risk","volume":"15","author":"Kim","year":"2008","journal-title":"J. Med. Screen."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(13)70279-1","article-title":"Air pollution and lung cancer incidence in 17 European cohorts: Prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE)","volume":"14","author":"Andersen","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.envres.2015.11.004","article-title":"The association between lung cancer incidence and ambient air pollution in China: A spatiotemporal analysis","volume":"144","author":"Guo","year":"2016","journal-title":"Environ. Res."},{"key":"ref_9","first-page":"23","article-title":"Drug resistance in lung cancer","volume":"1","author":"Shanker","year":"2010","journal-title":"Lung Cancer (Auckl)"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cncr.23542","article-title":"Bronchopulmonary neuroendocrine tumors","volume":"113","author":"Gustafsson","year":"2008","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","article-title":"A meta-analysis of thoracic radiotherapy for small-cell lung cancer","volume":"327","author":"Pignon","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cncr.10841","article-title":"Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America","volume":"95","author":"Janne","year":"2002","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihimaki","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"Coleman","year":"2011","journal-title":"Bone"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0035-1564807","article-title":"A Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast Cancer","volume":"6","author":"Sciubba","year":"2016","journal-title":"Glob. Spine J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1038\/srep18670","article-title":"Natural History of Non-Small-Cell Lung Cancer with Bone Metastases","volume":"5","author":"Santini","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: A retrospective study","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1061186X.2014.950668","article-title":"The critical role of bisphosphonates to target bone cancer metastasis: An overview","volume":"23","author":"Singh","year":"2015","journal-title":"J. Drug Target."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.medcli.2017.10.019","article-title":"Update on osteoporosis treatment","volume":"150","author":"Nogues","year":"2018","journal-title":"Med. Clin. (Barc)"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Garganta, M.D., Jaser, S.S., Lazow, M.A., Schoenecker, J.G., Cobry, E., Hays, S.R., and Simmons, J.H. (2018). Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta. BMC Musculoskelet. Disord., 19.","DOI":"10.1186\/s12891-018-2252-y"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"70869","DOI":"10.18632\/oncotarget.12281","article-title":"Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13569-016-0046-2","article-title":"Zoledronic acid in metastatic osteosarcoma: Encouraging progression free survival in four consecutive patients","volume":"6","author":"Conry","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminoncol.2003.08.017","article-title":"Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors","volume":"30","author":"Lacerna","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12935-019-0745-x","article-title":"Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer","volume":"19","author":"Akoury","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: A review","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5693\/djo.02.2017.08.002","article-title":"Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature","volume":"23","author":"Umunakwe","year":"2017","journal-title":"Digit. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2106\/JBJS.I.00518","article-title":"Locally delivered bisphosphonate for enhancement of bone formation and implant fixation","volume":"91","author":"Bobyn","year":"2009","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00776-009-1352-9","article-title":"Effect of locally administered zoledronic acid on injury-induced intramembranous bone regeneration and osseointegration of a titanium implant in rats","volume":"14","author":"Miettinen","year":"2009","journal-title":"J. Orthop. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/ten.teb.2011.0737","article-title":"Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants","volume":"18","author":"Cattalini","year":"2012","journal-title":"Tissue Eng. Part B Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1016\/j.actbio.2014.07.012","article-title":"Vertebroplasty using bisphosphonate-loaded calcium phosphate cement in a standardized vertebral body bone defect in an osteoporotic sheep model","volume":"10","author":"Verron","year":"2014","journal-title":"Acta Biomater."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jbo.2017.01.001","article-title":"Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration","volume":"6","author":"Nooh","year":"2017","journal-title":"J. Bone Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1557\/adv.2019.156","article-title":"3D-Printed Nanoporous Scaffolds Impregnated with Zoledronate for the Treatment of Spinal Bone Metastases","volume":"4","author":"Akoury","year":"2019","journal-title":"MRS Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2004.06.003","article-title":"Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines","volume":"47","author":"Matsumoto","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2008.12.019","article-title":"Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells","volume":"278","author":"Chang","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"Orlandi","year":"2011","journal-title":"Cell Prolif."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","article-title":"Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: A multicenter clinical trial","volume":"11","author":"Carteni","year":"2006","journal-title":"Oncologist"},{"key":"ref_41","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/scbi.2001.0416","article-title":"Critical determinants of metastasis","volume":"12","author":"Fidler","year":"2002","journal-title":"Semin. Cancer Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","article-title":"The microenvironment of the tumour-host interface","volume":"411","author":"Liotta","year":"2001","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"79503","DOI":"10.18632\/oncotarget.12806","article-title":"KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models","volume":"7","author":"Kenessey","year":"2016","journal-title":"Oncotarget"},{"key":"ref_46","first-page":"4418","article-title":"The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases","volume":"61","author":"Hiraga","year":"2001","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1016\/S0021-9258(18)67143-1","article-title":"Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose","volume":"261","author":"Hauschka","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1073\/pnas.84.7.2024","article-title":"Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones","volume":"84","author":"Pfeilschifter","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF00133470","article-title":"Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone","volume":"10","author":"Kostenuik","year":"1992","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: Causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10585-012-9563-4","article-title":"Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer","volume":"30","author":"Futamura","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cas.13155","article-title":"Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications","volume":"108","author":"Ishiguro","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/adt.2014.573","article-title":"Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors","volume":"12","author":"Edmondson","year":"2014","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"40006","DOI":"10.1021\/acsami.7b11423","article-title":"Sequential Delivery of Doxorubicin and Zoledronic Acid to Breast Cancer Cells by CB [7]-Modified Iron Oxide Nanoparticles","volume":"9","author":"Benyettou","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","article-title":"Bone metastasis targeting: A novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel","volume":"158","author":"Kumar","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3892\/ol.2017.6355","article-title":"Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors","volume":"14","author":"Koto","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.msec.2017.08.043","article-title":"High-activity chitosan\/nano hydroxyapatite\/zoledronic acid scaffolds for simultaneous tumor inhibition, bone repair and infection eradication","volume":"82","author":"Lu","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ahangar, P., Akoury, E., Ramirez Garcia Luna, A.S., Nour, A., Weber, M.H., and Rosenzweig, D.H. (2018). Nanoporous 3D-Printed Scaffolds for Local Doxorubicin Delivery in Bone Metastases Secondary to Prostate Cancer. Materials, 11.","DOI":"10.3390\/ma11091485"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.2147\/IJN.S33083","article-title":"Fabrication and characterization of a rapid prototyped tissue engineering scaffold with embedded multicomponent matrix for controlled drug release","volume":"7","author":"Chen","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/jacs.5b12357","article-title":"Photocleavable Hydrogel-Coated Upconverting Nanoparticles: A Multifunctional Theranostic Platform for NIR Imaging and On-Demand Macromolecular Delivery","volume":"138","author":"Jalani","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2018.09.042","article-title":"3D printing and coating to fabricate a hollow bullet-shaped implant with porous surface for controlled cytoxan release","volume":"552","author":"Yang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/jbm.b.31464","article-title":"Polycaprolactone coated porous tricalcium phosphate scaffolds for controlled release of protein for tissue engineering","volume":"91","author":"Xue","year":"2009","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.3390\/ijms160715118","article-title":"3D-Printed ABS and PLA Scaffolds for Cartilage and Nucleus Pulposus Tissue Regeneration","volume":"16","author":"Rosenzweig","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/acsbiomaterials.7b00801","article-title":"Controlled Release of Growth Factors from Multilayered Fibrous Scaffold for Functional Recoveries in Crushed Sciatic Nerve","volume":"4","author":"Hong","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15306","DOI":"10.1021\/acsami.9b02502","article-title":"Three-Dimensional Printed Polylactic Acid Scaffolds Promote Bone-like Matrix Deposition in vitro","volume":"11","author":"Fairag","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/8\/1212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:10:58Z","timestamp":1760188258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/8\/1212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":68,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["jcm8081212"],"URL":"https:\/\/doi.org\/10.3390\/jcm8081212","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]}}}